Connect with us

Life Sciences

Researchers awarded grant to study potential therapeutic avenues for facioscapulohumeral muscular dystrophy

Researchers in the Department of Human Nutrition, Foods, and Exercise in the Virginia Tech College of Agriculture and Life Sciences were awarded a nearly…

Published

on

This article was originally published by BioEngineering

Researchers in the Department of Human Nutrition, Foods, and Exercise in the Virginia Tech College of Agriculture and Life Sciences were awarded a nearly $130,000 grant from the venture philanthropy organization SOLVE FSHD to research potential therapeutic avenues for facioscapulohumeral muscular dystrophy.

Mice with facioscapulohumeral muscular dystrophy show normal muscle fibers after treatment with a targeted gene therapy. Image courtesy of Nationwide Children’s Hospital.

Credit: Image courtesy of Nationwide Children’s Hospital.

Researchers in the Department of Human Nutrition, Foods, and Exercise in the Virginia Tech College of Agriculture and Life Sciences were awarded a nearly $130,000 grant from the venture philanthropy organization SOLVE FSHD to research potential therapeutic avenues for facioscapulohumeral muscular dystrophy.

Facioscapulohumeral muscular dystrophy (FSHD) is a rare genetic neuromuscular disorder that progressively weakens and atrophies muscles. It takes its name from the areas of the body it typically affects: the facial muscles (facio-), shoulder blades (scapulo-), and upper arms (humeral). Although it affects a relatively small number of individuals, with an estimated prevalence of 1 in 8,000, it can profoundly impact those who have it and their families.

Professor Robert Grange, assistant department head of human nutrition, foods, and exercise and director of the Metabolism Core at Virginia Tech, is one of the investigators on the project. His research will center on assessing skeletal muscle torque as a functional outcome measure in a specialized mouse model of facioscapulohumeral muscular dystrophy. By focusing on this mouse model, Grange aims to unravel critical insights into the underlying mechanisms of the disorder and develop innovative strategies for intervention and treatment.

Grange will partner with Scott Harper, a distinguished researcher from Nationwide Children’s Hospital who developed the facioscapulohumeral muscular dystrophy mouse model used in the funded study. Their combined expertise in muscle biology and genetic disorders ensures a comprehensive approach to tackling the challenges posed by the disorder. 

This research project was selected as one of four initiatives to receive funding from Solve FSHD’s recent Collaborative Grant award. Solve FSHD, a leading organization dedicated to accelerating FSHD research, awarded a total of $1.4 million toward projects embracing collaboration between institutions to catalyze and enhance novel potential therapeutics for FSHD.



life sciences

Life Sciences

Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…

Continue Reading
Life Sciences

Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner

The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….

Continue Reading

Trending